Michael J. Inserra
Known title: DirectorCIK: 0002017848
Michael J. Inserra's purchase track record
Michael J. Inserra has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/30/2024 | BHF | $108K | +4.9% | +19.9% | +15.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BHF | ▲ Buy | Option Exercise | 1,418 | $0 | 6/2/2026 | View on chart |
| BHF | ▲ Buy | Option Exercise | 1,925 | $0 | 6/6/2025 | View on chart |
| BHF | ▲ Buy | Option Exercise | 273 | $0 | 6/6/2024 | View on chart |
| BHF | ▲ Buy | Open Market | 2,500 | $108K | 5/30/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
BHF Analyst Target Cut to $57, Rating Upgrade Amid Market Attention
KBW lowered its price target for BHF to $57, while a rating upgrade is expected after a pending acquisition. The stock has attracted attention following a 24% drop and its inclusion among life‑insurance names sensitive to rising Treasury yields. These developments add context to BHF’s valuation, which sits at a trailing P/E of 3.4 and an analyst average target of $65.
BHF Analyst Target Cut to $57, Rating Upgrade Amid Market Attention. KBW lowered its price target for BHF to $57, while a rating upgrade is expected after a pending acquisition. The stock has attracted attention following a 24% drop and its inclusion among life‑insurance names sensitive to rising Treasury yields. These developments add context to BHF’s valuation, which sits at a trailing P/E of 3.4 and an analyst average target of $65.